Stockscreener 앱 받기
0.6045
3.74%
-0.0235
시간 외 거래:
.62
0.0155
+2.56%
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
StockNews.com Upgrades CEL-SCI (NYSE:CVM) to “Hold” - Defense World
CVM stock touches 52-week low at $0.68 amid sharp annual decline - Investing.com India
CEL-SCI, FDA agree on Multikine trial design (CVM:NYSE) - Seeking Alpha
FDA agrees with CEL-SCI's patient selection for cancer study - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
CEL-SCI (FRA:LSRM) Free Cash Flow : €-17.72 Mil (TTM As of Jun. 2024) - GuruFocus.com
CVM stock touches 52-week low at $0.87 amid market challenges - Investing.com Australia
CVM stock touches 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
FDA panel challenges PD-L1 inhibitors, CEL-SCI's Multikine shows promise - Investing.com
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Yahoo Finance
Conestoga Capital Advisors Sold National Research Corp. (NRC), as it Fell Short of Expectations - Yahoo Finance UK
CVM stock touches 52-week low at $0.93 amid market challenges - Investing.com India
Exploring Opportunities in the Therapeutic Vaccines Market: - openPR
CVM stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CEL-SCI (NYSE:CVM) Trading Down 3.8%Here's What Happened - MarketBeat
SEC Form POS AM filed by Cel-Sci Corporation - Quantisnow
A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine - Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Yahoo Finance
Annaly Capital Management Inc [NLY] CEO and CIO makes an insider purchase of 50,000 shares worth 1.0 million. - Knox Daily
CVM Stock Sees Decline of Approximately -6.25% in Last Five Days - Knox Daily
How to interpret Cel-Sci Corp. (CVM)’s stock chart patterns - US Post News
Cel-Sci Corp.’s Market Journey: Closing Weak at 1.05, Down -1.87 - The Dwinnex
Healthcare Stock Performance - Yahoo Finance
CEL-SCI Co. (NYSE:CVM) Position Raised by Thoroughbred Financial Services LLC - Defense World
Celonis expands alliance with Samsung for process optimisation - Yahoo! Voices
Stifel Upgrades Celestica Inc. (CLS) to Buy from Hold - Insider Monkey
Creo Sells Stake of Subsidiary to Chinese Market-Leader - Business News Wales
Celonis Expands Partnership with Samsung Fire & Marine Insurance to Optimize Processes and to Drive Value - Business Wire
Check out these key findings about Complete Solaria Inc. (CSLR) - SETE News
Trend Tracker for (CLS) - Stock Traders Daily
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Investing in Complete Solaria Inc. (CSLR) Is Getting More Attractive - Knox Daily
CVM’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Exact Sciences Debuts Positive Topline Results for Trial of Blood-Based Colorectal Cancer Screening Algorithm - Patient Care Online
Potential Price Increase for Cel-Sci Corp. (CVM) After Recent Insider Activity - Knox Daily
ESMO: Exact Sciences shows off early colorectal cancer blood test data - Fierce Biotech
Multikine shows promise in head and neck cancer study - Investing.com
Healthy Upside Potential: Celestica, Inc. (CLS) - SETE News
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial - Medical Device Network
CEL-SCI Corp's (CVM) Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - StreetInsider.com
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation – Company AnnouncementFT.com - Financial Times
Exact Sciences announces data for CRC screening test - TipRanks
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Yahoo Finance
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 - Business Wire
Celestica Inc. (CLS): Among the Worst Performing AI Stocks of Previous Week - Insider Monkey
Creighton loses top-10 matchup, falling in fifth set to No. 4 Louisville - Kearney Hub
Global Therapeutic Vaccines Market by Method, Application and Forecast 2024-2032 - 대구포스트
Cel-Sci Corp. (CVM) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Understanding the Risks of Investing in Cel-Sci Corp. (CVM) - Knox Daily
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress - Yahoo Finance
UTHR Shares Experience Surge in Value - Knox Daily
A company insider recently bought 20,000 shares of Cel-Sci Corp. [CVM]. Should You Buy? - Knox Daily
BKNG Shares Experience Decline in Value - Knox Daily
CEL-SCI gains UK pediatric waiver for cancer treatment - Investing.com
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Business Wire
0.93%
3.55%
자본화:
|
볼륨(24시간):